- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01492686
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
June 26, 2018 updated by: Mitsubishi Tanabe Pharma Corporation
Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner.
The study is also to examine the safety of MCI-186 to the ALS patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
137
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients whose conditions are defined as "definite ALS"or "probable ALS"diagnostic criteria El Escorial and revised Airlie House.
- Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.
- Patients of less than 2 years after the onset of ALS.
- Patients whose progress of the condition during 12 weeks before administration meet other requirements.
Exclusion Criteria:
- Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.
- Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.
- Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.
- In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
|
Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle).
The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
|
PLACEBO_COMPARATOR: Arm 2
|
All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle).
The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
Time Frame: baseline and 24 weeks
|
0=worst; 48=best
|
baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Death or a Specified State of Disease Progression
Time Frame: 24 weeks
|
Any of "death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech" was defined as an event.
|
24 weeks
|
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
Time Frame: baseline and 24 weeks
|
baseline and 24 weeks
|
|
Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks
Time Frame: baseline and 24 weeks
|
The Modified Norris Scale is a measure of movement disorder for patients with ALS.
0=worst; 102=best
|
baseline and 24 weeks
|
Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks
Time Frame: baseline and 24 weeks
|
The ALSAQ40 score is a measure of QoL for patients with ALS.
The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions.
200=worst; 40=best
|
baseline and 24 weeks
|
Percentage of Participants With Adverse Events
Time Frame: 24 weeks
|
24 weeks
|
|
Percentage of Participants With Adverse Drug Reactions
Time Frame: 24 weeks
|
24 weeks
|
|
Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of "Investigations" (PT, MedDRA Ver. 17.0)
Time Frame: 24 weeks
|
24 weeks
|
|
Percentage of Participants With Abnormal Values in Sensory Examinations
Time Frame: baseline and 24 weeks
|
baseline and 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
- WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269.
- Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):49-54. doi: 10.1080/21678421.2017.1361443.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (ACTUAL)
September 1, 2014
Study Completion (ACTUAL)
October 1, 2014
Study Registration Dates
First Submitted
December 11, 2011
First Submitted That Met QC Criteria
December 14, 2011
First Posted (ESTIMATE)
December 15, 2011
Study Record Updates
Last Update Posted (ACTUAL)
December 31, 2018
Last Update Submitted That Met QC Criteria
June 26, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Neuroprotective Agents
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Edaravone
Other Study ID Numbers
- MCI186-19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis (ALS)
-
Northwestern UniversityCompletedAmyotrophic Lateral Sclerosis (ALS) | Lou Gehrig's Disease | Primary Lateral Sclerosis (PLS) | Familial Amyotrophic Lateral Sclerosis | ALS With Frontotemporal Dementia (ALS/FTD) | Motor Neuron Disease (MND) | Sporadic ALS (SALS)United States
-
Dallas VA Medical CenterRecruitingAmyotrophic Lateral Sclerosis (ALS)United States
-
St. Joseph's Hospital and Medical Center, PhoenixEmory University; Mitsubishi Tanabe Pharma America Inc.Active, not recruitingALS (Amyotrophic Lateral Sclerosis)United States
-
Taipei Veterans General Hospital, TaiwanUnknownDevelopment and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.ALS (Amyotrophic Lateral Sclerosis)Taiwan
-
Brainstorm-Cell TherapeuticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Phoenix Neurological Associates, LTDInstitute for EthnomedicineUnknown
-
Skulpt, Inc.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
Clinical Trials on MCI-186
-
Mitsubishi Tanabe Pharma CorporationTerminated
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Mitsubishi Tanabe Pharma CorporationCompletedAcute Ischemic Stroke (AIS)Netherlands, Finland, United Kingdom
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma AmericaCompletedHealthy | Hepatic ImpairmentJapan
-
Mitsubishi Tanabe Pharma AmericaCompletedHealthy | Renal ImpairmentJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy | Severe Hepatic ImpairmentCzechia, Hungary, Slovakia